Enanta Pharmaceuticals, Inc.
ENTA
$11.44
$0.090.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -7.82% | 23.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.82% | 23.07% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -7.82% | 23.07% | |||
| SG&A Expenses | 6.20% | -7.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.87% | -10.87% | |||
| Operating Income | -5.32% | 38.80% | |||
| Income Before Tax | -9.82% | 36.18% | |||
| Income Tax Expenses | -70.83% | -25.00% | |||
| Earnings from Continuing Operations | -9.66% | 36.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.66% | 36.16% | |||
| EBIT | -5.32% | 38.80% | |||
| EBITDA | -6.19% | 41.39% | |||
| EPS Basic | -8.55% | 52.52% | |||
| Normalized Basic EPS | -8.89% | 54.92% | |||
| EPS Diluted | -8.55% | 52.52% | |||
| Normalized Diluted EPS | -8.89% | 54.92% | |||
| Average Basic Shares Outstanding | 1.02% | 34.46% | |||
| Average Diluted Shares Outstanding | 1.02% | 34.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||